Moderna, Inc.: insider trades · United States · SEC (Form 4)

About Moderna, Inc.

Moderna, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ under the ticker MRNA. Headquartered in Cambridge, Massachusetts, United States, Moderna has become one of the best-known names in messenger RNA technology. Founded in 2010 and listed publicly in 2018, the company was built around a single strategic idea: using an mRNA platform to design, develop, and commercialize vaccines and therapeutics more rapidly than conventional drug-development models. For investors, Moderna’s appeal lies in its platform economics. It is not a one-product biotech, but a technology-driven company seeking to industrialize mRNA design across multiple therapeutic areas. Its commercial portfolio now includes several approved products, notably Spikevax, its COVID-19 vaccine, mRESVIA, its RSV vaccine, and mNEXSPIKE, which was launched commercially in 2025. Beyond these marketed assets, Moderna is advancing a broader pipeline across infectious diseases and oncology, including programs in seasonal influenza, cytomegalovirus, RSV, and cancer. That pipeline diversification matters because the company is working to reduce dependence on the post-pandemic COVID franchise and build a more durable long-term revenue base. From a competitive standpoint, Moderna remains a global leader in mRNA science, but it competes in a highly crowded and capital-intensive arena against large pharmaceutical and biotech peers with deep regulatory and commercial capabilities. Its core advantage is the combination of scientific platform breadth, clinical execution, and speed of development. At the same time, the company faces normalizing demand for COVID vaccines, pricing and volume pressure, and continued heavy investment requirements in research, manufacturing, and global commercialization. Recent developments underscore this transition. Moderna’s 2025 and early 2026 disclosures point to expanding commercial traction, meaningful cost reductions, new phase 3 trial activity, and ongoing regulatory progress for future vaccines, including its seasonal flu program. The company has also highlighted geographic expansion efforts and international approvals or filings designed to broaden access outside the United States. For investors, Moderna should be viewed as a high-R&D, platform-oriented growth story whose valuation remains tied to the clinical, regulatory, and commercial success of its mRNA pipeline.